Medicine
Yargesa 100 mg capsule
Yargesa 100 mg capsule is a prescription medicine containing Miglustat for oral use, marketed by Edenbridge Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F). Excursions are permitted between 15°C to…
Key facts
- Active ingredient (INN)
- Miglustat
- Brand
- Yargesa
- Strength
- 100 mg
- Dosage form
- Capsule
- Route
- Oral
- Packs
- 1 blister pack
- Marketing authorisation holder
- Edenbridge Pharmaceuticals
- Manufacturer
- Edenbridge Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F). Excursions are permitted between 15°C to 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A16AX06 Miglustat
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 6 August 2020
- Identifiers
- RxCUI 401938, 2642350DailyMed set ID 2b371dfe-e2b0-47fe-b677-a7bde7149f87NDC 42799-709Application ANDA209821
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 blister pack in 1 carton / 15 capsule in 1 blister pack | 42799-709-15 | Edenbridge Pharmaceuticals | 31 October 2023 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Miglustat 100 mg capsule.
Other strengths and forms of Miglustat
Clinical summary
Miglustat is a glucosylceramide synthase inhibitor indicated as monotherapy for treatment of adult patients with mild/moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option. MedsAcross supplies Miglustat for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about MiglustatFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Miglustat prescribing information (CoTherix) · U.S. National Library of Medicine, DailyMed
- Opfolda: European public assessment report (EPAR) · European Medicines Agency
- Zavesca: European public assessment report (EPAR) · European Medicines Agency
Need Yargesa 100 mg capsule for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.